Shilpa Medicare’s JV Oncosol Gets FDA Nod for IMKELDI

28 Nov 2024 , 12:41 AM

Shilpa Medicare’s joint venture Oncosol, with Shorla Oncology, has gained US FDA approval for IMKELDI, an imatinib oral solution. IMKELDI is the first liquid form of imatinib, and it will be approved for use in specific cases of cancers. Oral liquid formulation is the advanced drug form of imatinib for precise dosing.

IMKELDI is applied in the treatment of chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome/myeloproliferative disease (MDS/MPD), and gastrointestinal stromal tumors (GIST).

This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms. IMKELDI hopes to enhance the treatment outcome for the patients by providing a more convenient liquid form of the medication. The approval of IMKELDI is a milestone that has furthered the ground for Shilpa Medicare and Oncosol in this oncology market.